{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}],"title":"Any Grade 3, 4, and/or 5 Serious Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}],"title":"Grade 3 Non-serious Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}],"title":"Grade 3 Non-serious Anorexia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}],"title":"Grade 3 Non-serious Hypokalemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}],"title":"Grade 3 Platelet count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}],"title":"Grade 4 Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}],"title":"Grade 4 Platelet count decreased"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"3"}],"units":"Participants"}],"description":"Treatment emergent grades 3, 4, and/or 5 adverse events possibly related grouped by relationship to the study drug (e.g., lenalidomide, romidepsin, CC-486 (5-azacitidine) in any combinations) assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 3 is severe. Grade 4 is life threatening. Grade 5 is death related to adverse event.","groups":[{"description":"Arm 2, Cohort 2, Dose Level 2: adverse events possibly related to lenalidomide.","id":"OG000","title":"Arm 2, Cohort 2, Dose Level 2 - Dose Expansion Related to Lenalidomide"},{"description":"Arm 2, Cohort 2, Dose Level 2: adverse events possibly related to romidepsin.","id":"OG001","title":"Arm 2, Cohort 2, Dose Level 2 - Dose Expansion Related to Romidepsin"},{"description":"Arm 2, Cohort 2, Dose Level 2: adverse events possibly related to CC-486 (5-azacitidine).","id":"OG002","title":"Arm 2, Cohort 2, Dose Level 2 - Dose Expansion Related to CC-486 (5-azacitidine)"},{"description":"Arm 2, Cohort 2, Dose Level 2: adverse events possibly related to any combination.","id":"OG003","title":"Arm 2, Cohort 2, Dose Level 2 - Dose Expansion Related to Any Combination"},{"description":"Arm 2, Cohort 2, Dose Level 4: adverse events possibly related to lenalidomide.","id":"OG004","title":"Arm 2, Cohort 2, Dose Level 4 - Dose Expansion Related to Lenalidomide"},{"description":"Arm 2, Cohort 2, Dose Level 4: adverse events possibly related to romidepsin.","id":"OG005","title":"Arm 2, Cohort 2, Dose Level 4 - Dose Expansion Related to Romidepsin"},{"description":"Arm 2, Cohort 2, Dose Level 4: adverse events possibly related to CC-486 (5-azacitidine).","id":"OG006","title":"Arm 2, Cohort 2, Dose Level 4 - Dose Expansion Related to CC-486 (5-azacitidine)"},{"description":"Arm 2, Cohort 2, Dose Level 4: adverse events possibly related to any combination.","id":"OG007","title":"Arm 2, Cohort 2, Dose Level 4 - Dose Expansion Related to Any Combination"},{"description":"Arm 3, Cohort 2, Dose Level 4: adverse events possibly related to lenalidomide.","id":"OG008","title":"Arm 3, Cohort 2, Dose Level 4 - Dose Expansion Related to Lenalidomide"},{"description":"Arm 3, Cohort 2, Dose Level 4: adverse events possibly related to romidepsin.","id":"OG009","title":"Arm 3, Cohort 2, Dose Level 4 - Dose Expansion Related to Romidepsin"},{"description":"Arm 3, Cohort 2, Dose Level 4: adverse events possibly related to CC-486 (5-azacitidine).","id":"OG010","title":"Arm 3, Cohort 2, Dose Level 4 - Dose Expansion Related to CC-486 (5-azacitidine)"},{"description":"Arm 3, Cohort 2, Dose Level 4: adverse events possibly related to any combination.","id":"OG011","title":"Arm 3, Cohort 2, Dose Level 4 - Dose Expansion Related to Any Combination"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 cycles (each cycle is 28 days)","title":"Arm 2, Cohort 2, Dose Level 2 and 4; and Arm 3, Cohort 2, Dose Level 4 Treatment Emergent Serious Grades 3, 4, and/or 5 Adverse Events Possibly Related to Drug Grouped by Relationship to the Study Drug and/or Combination","type":"PRIMARY","unitOfMeasure":"adverse events"}